Levodopa Market to Reach $2.9 Billion Globally By 2032 at 6.1% CAGR: Allied Market Research

The increasing prevalence of Parkinson’s disease, rising healthcare expenditure, and technological advancements in drug delivery are projected to drive the global levodopa market’s growth during the forecast period. The North America region is predicted to witness prominent growth by 2032.

Wilmington, New Castle, Delaware, April 23, 2024 (GLOBE NEWSWIRE) — Allied Market Research has recently published a report, titled, Levodopa Market Size, Share, Competitive Landscape and Trend Analysis Report by Form, by Route of Administration, by Distribution Channels: Global Opportunity Analysis and Industry Forecast, 2023-2032.” According to the report, the global levodopa market generated $1.7 billion in 2022, and is anticipated to generate $2.9 billion by 2032, rising at a CAGR of 6.1% from 2023 to 2032. 

Prime Determinants of Growth 

The growing prevalence of Parkinson’s disease, the increasing demand for therapeutic Interventions, and the increasing healthcare expenditure are the factors expected to drive the growth of the global levodopa market in the forecast period from 2023 to 2032. However, the side effects and safety concerns associated with the levodopa may hamper the market growth in the coming future. On the contrary, the development of novel formulations and efficient drug delivery methods and technological advancements in drug delivery are expected to offer remunerative opportunities for the expansion of the levodopa market during the forecast period. 

Request Sample of the Report on Levodopa Market Forecast 2032: https://www.alliedmarketresearch.com/request-sample/A213646 

Report Coverage & Details: 

Report Coverage  Details 
Forecast Period  2023–2032 
Base Year  2022 
Market Size in 2022  $1.7 billion 
Market Size in 2032  $2.9 billion 
CAGR  6.1% 
No. of Pages in Report  300 
Segments covered  Form, Route of Administration, Distribution Channels, and Region 
Drivers  Rising prevalence of Parkinson’s disease  Rise in healthcare expenditure  Growing demand for therapeutic Interventions 
Opportunities  Technological advancements in drug delivery  Development of novel formulations and efficient drug delivery methods 
Restraints  Safety concerns and side effects 

Procure Complete Report (300 Pages PDF with Insights, Charts, Tables, and Figures): https://www.alliedmarketresearch.com/checkout-final/levodopa-market-A213646 

Form: Tablets Sub-segment to be the Most Dominant During the Forecast Period 

The tablets sub-segment accounted for the largest global levodopa market share of 36.0% in 2022 and is expected to grow at the highest CAGR of 7.0% during the forecast period. Levodopa tablets are favored for their convenience, affordability, and widespread adoption among patients. Offering a simple and familiar mode of administration, tablets enhance patient adherence to treatment routines. Moreover, the availability of various tablet strengths allows for flexible dosing tailored to individual patient needs, optimizing therapeutic outcomes. Additionally, tablets are relatively cost-effective compared to alternative formulations, ensuring accessibility to a broader patient population.  

Route of Administration: Oral Sub-segment to Flourish Immensely During the Forecast Period 

The oral sub-segment accounted for the largest market share of 57.7% in 2022 and dominate in terms of market share by 2032. This dominance is majorly owing to the convenience, familiarity, and widespread adoption of oral administration among patients and healthcare providers. With various dosages available, patients can easily adhere to treatment regimens. Additionally, the accessibility and versatility of the oral route make it a preferred choice, especially in early to mid-stage Parkinson’s disease. 

Distribution Channels: Retail Pharmacies Sub-segment to Grow Prominently During the Forecast Period 

The retail pharmacies sub-segment accounted for the largest market share of 34.1% in 2022 and is predicted to witness prominent growth by 2032. This is majorly because the widespread accessibility of retail pharmacies provides convenient access to levodopa for patients managing Parkinson’s disease. Additionally, the presence of trained pharmacists in retail settings offers personalized guidance and support to patients, enhancing treatment adherence and satisfaction. Furthermore, retail pharmacies often stock a variety of medications, including levodopa, allowing patients to fulfill their prescriptions conveniently. 

Region: North America Market to Hold Major Share by 2032 

The levodopa market in the North America region accounted for the largest share of 40.9% in 2022 and is predicted to continue to maintain its dominance in terms of market share during the forecast period. The robust healthcare infrastructure and advanced medical research facilities in North America foster innovation in Parkinson’s disease management. This environment encourages the development of novel levodopa formulations and treatment approaches, driving market growth. Besides, the region’s high prevalence of Parkinson’s disease, combined with an aging population, and supportive healthcare policies contributes to the growth of the levodopa market in North America. 

Request For Custom Report: https://www.alliedmarketresearch.com/request-for-customization/A213646 

Leading Players in the Levodopa Market: 

  • UCB SA 
  • Mylan Nv 
  • Eli Lilly and Company 
  • Teva Pharmaceutical Industries Ltd. 
  • Bristol-Myers Squibb Co. 
  • Sun Pharmaceutical Industries Ltd. 
  • Pfizer Inc. 
  • Merck and Co. Inc. 
  • Impax Laboratories Inc. 
  • Novartis AG 

The report provides a detailed analysis of the key players of the global levodopa market. These players have adopted different strategies, such as new product launches, collaborations, expansion, joint ventures, agreements, and others to increase their market share and maintain their dominance in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario. 

AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model) Offered by Allied Market Research: 

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports. 

Get an access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access 

About Allied Market Research: 

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI. 

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.  

Contact 
David Correa 

1209 Orange Street, 

Corporation Trust Center, 

Wilmington, New Castle, 

Delaware 19801 USA. 

Toll Free: +1-800-792-5285 

Int’l: +1-503-894-6022 

UK: +44-845-528-1300 

Hong Kong: +852-301-84916 

India (Pune): +91-20-66346060 

Fax: +1-855-550-5975 

help@alliedmarketresearch.com   

Web: https://www.alliedmarketresearch.com    

Follow Us on: LinkedIn Twitter 

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Privacy & Cookies Policy